Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

International Clinical Psychopharmacology

Volumn 18, Issue 4, 2003, Pages 211-217

  Lepola, Ulla M ^a,b,c   Loft, Henrik ^d   Reines, Elin Heldbo ^d  

^a Kuopion Psykiatripalvelu Oy   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d H LUNDBECK A S   (Denmark)

Author keywords

Antidepressant; Citalopram; Efficacy; Enantiomer; Escitalopram; Flexible dose; MADRS; Major depressive disorder; SSRI

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERHIDROSIS; IMPOTENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINITIS; SINGLE BLIND PROCEDURE; SOMNOLENCE; XEROSTOMIA;

EID: 0038441914     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200307000-00003     Document Type: Article

References (22)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM-IV). Washington DC: American Psychiatric Association.
2. Bostwick JM, Pankratz VS (2000). Affective disorders and suicide risk: a reexamination. Am J Psychiatry 157:1925-1932.
3. Burke WJ, Gergel I, Bose A (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336.
4. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL (1993). The enduring psychosocial consequences of mania and depression. Am J Psychiatry 150:720-727.
5. Declaration of Helsinki (1997). Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 277:925-926.
6. Entsuah R, Shaffer M, Zhang J (2002). A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects. J Psychiatr Res 36:437.
7. Feighner JP, Overø K (1999). Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J. Clin. Psychiatry 60:824-830.
8. Gorman JM, Korotzer A, Su G (2002). Efficacy comparison of escitalopram and citalopram in treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 7 (suppl 1):40-44.
9. Guy W (1976). ECDU Assessment Manual for Psychopharmacology, rev. edn. US Department of Health, Education and Welfare. Publication No. (ADM) 218-222. Rockville, MD: National Institutes of Mental Health.
10. Hyttel J, Bogesø KP, Perregaard J, Sanchez C (1992). The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm 88:157-160.
11. Katon W, Schulberg H (1992). Epidemiology of depression in primary care. Gen Hospital Psychiatry 14:237-248.
12. Lepine JP, Gastpar M; Mendlewicz J, Tylee A (1997). Depression in the community: the first pan-European study DEPRESS (Depression Research in European Society). Int Clin Psychopharmacol 12:19-29.
13. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
14. Montgomery SA, Roberts A, Patel AG (1994). Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharmacol 9 (suppl 1):49-53.
15. Montgomery SA, Loft H, Sanchez C, Reines EH, Papp M (2001). Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88:282-286.
16. Murray CJL, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349:1498-1503.
17. Mørk A, Kreilgaard M, Sanchez C, Brennum LT, Wiborg O (2002). Escitalopram: a comparative study of the in vitro and in vivo 5-HT uptake inhibitory activity. Int J Neuropsychopharm 5(suppl 1):66.
18. Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350.
19. Rudolph RL, Feiger AD (1999). A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56:171-181.
20. Sanchez C, Bergqvist PBF, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O (2003). Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167:353-362.
21. Stahl SM, Nierenberg AA, Gorman JM (2001). Evidence of early onset of antidepressant effect in randomised controlled trials. J. Clin Psychiatry 62 (suppl 4):17-23.
22. Wade A, Lemming OM, Hedegaard KB (2002). Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17:95-102.